A
Aclaris Therapeutics
Aclaris Therapeutics (ACRS) | Dermatology Pharmaceutical Company
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company that was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. The company focuses on the development of novel drug candidates for immuno-inflammatory diseases. Its lead product candidate, zunsemetinib, is an oral small molecule inhibitor of MK2, which is involved in the inflammatory signaling cascade. Zunsemetinib is being investigated for the treatment of various conditions, including rheumatoid arthritis and psoriatic arthritis. Another key candidate is ATI-1777, a topical 'soft' JAK 1/3 inhibitor aimed at treating atopic dermatitis.
The company was founded by Dr. Neal Walker, Dr. Christopher Powala, Frank Ruffo, and Dr. Stuart D. Shanler. Dr. Walker, a board-certified dermatologist, has a background in co-founding and leading several life sciences companies, including Vicept Therapeutics. This experience in dermatology and company building has been foundational to Aclaris's strategic direction. The company's business model revolves around identifying and developing promising drug candidates through the clinical trial process. Revenue is primarily generated through collaborations, licensing agreements, and, upon potential approval, the commercialization of its therapeutic products.
Aclaris Therapeutics has undergone strategic shifts, including the sale of its commercial dermatology business to focus purely on its development pipeline for immuno-inflammatory conditions. The company actively engages in clinical trials to advance its portfolio; for example, a Phase 2b trial for zunsemetinib in rheumatoid arthritis has been completed, and the company continues to evaluate its potential in other inflammatory diseases. The firm targets a market with significant unmet needs, aiming to provide new treatment options for patients with chronic inflammatory conditions.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2012
- Headquarters
- Malvern, United States
- Listing
- IPO 2015
- Employees
- 77
- Open positions
- 1
- Dealroom signal
- 91.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Dermatology, Biotech and Pharma, Woman Founder, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Aug 2017
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT VCOther financing | Nov 2024 | $80M | — | Adage Capital · Rock Springs Capital · Vivo Capital · Samsara BioCapital | ↗ |
| POST IPO EQUITYOther financing | Jun 2016 | $20M | — | Aisling Capital | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $5.7M | -27% | −$68M | -1181.6% |
| 2025 | $7.8M | -58.2% | −$68M | -862.6% |
| 2024 | $19M | -40.1% | $38M | 201.3% |
| 2023 | $31M | +5% | −$134M | -430.1% |
| 2022 | $30M | +340.1% | −$80M | -267.7% |
| 2021 | $6.8M | +4.3% | −$41M | -607.1% |
| 2020 | $6.5M | — | −$51M | -785.4% |
Growth signals
Latest recorded traffic for Aclaris Therapeutics is 6.2K monthly website visits, down 78.6% over the last three months. Aclaris Therapeutics's team grew 18.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
F-Prime
Vivo Capital
Sofinnova Investments
Series B and later5 investors entered at this stage
RA Capital Management
Aperture Ventures Partners
Rock Springs Capital
Cormorant Asset Management
Aisling Capital
Other known investors5 additional known investors
Adage Capital
Decheng Capital
Forge Life Science Partners
Logos Capital
Samsara BioCapital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aclaris Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aclaris Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.